Immix Biopharma, Inc.IMMX
Price (close)
$11.70
Market cap
$837.0M
P/E
—
Revenue (TTM)
—
Net income
-$39.9M
Dividend yield
—
1-year total return
473.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Immix Biopharma, Inc. does.
Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy (“CAR-T”)
in light chain (AL) Amyloidosis and other serious diseases. Our lead cell therapy candidate is CAR-T NXC-201 (“NXC-201”),
currently being evaluated in our ongoing United States Phase 1b/2 NEXICART-2 (NCT06097832) clinical trial and an ex-U.S. phase 1b/2a
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$1.1M | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M |
| Free cash flow | — | -$1.6M | — | -$11.4M | -$15.8M | -$24.7M |
More on IMMX.
- Immix Biopharma, Inc. summary
- Immix Biopharma, Inc. financial statements
- Immix Biopharma, Inc. key metrics
- Immix Biopharma, Inc. health scores and style box
- Immix Biopharma, Inc. earnings
- Immix Biopharma, Inc. dividends
- Immix Biopharma, Inc. valuation
- Immix Biopharma, Inc. ownership and insiders
- Immix Biopharma, Inc. peers
Figures from Immix Biopharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.